ReviewBone marrow transplantation2016
Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 60 citations in OpenAlex.
- Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.Blood cancer journal · 2023Article
- Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.Nature communications · 2022Article
- Review
- Immunotherapy for the treatment of multiple myeloma.Frontiers in immunology · 2022Review
- Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma.Bone marrow transplantation · 2021Article
- Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.Stem cell research & therapy · 2021Review
- Boosting Immunity against Multiple Myeloma.Cancers · 2021Review
- Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.Bone marrow transplantation · 2021Review
- Allogeneic Hematopoietic Transplantation for Multiple Myeloma in the New Drugs Era: A Platform to Cure.Journal of clinical medicine · 2020Review
- Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation.CPT: pharmacometrics & systems pharmacology · 2020Article
- Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost.International journal of hematology · 2020Review
- Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.Haematologica · 2019Article
- Survival analysis of multiple myeloma patients after autologous stem cell transplantation.Stem cell investigation · 2019Article
- [Diagnostic and therapeutic considerations on recurrence of multiple myeloma : A current overview].Der Internist · 2019Review
- Review
- [Multiple myeloma : What has been confirmed in therapy?]Der Internist · 2017Review
- Donor T-cell responses and disease progression patterns of multiple myeloma.Bone marrow transplantation · 2017Article
- Current Review on High-Risk Multiple Myeloma.Current hematologic malignancy reports · 2017Review
- Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2017Review
- Role of stem cell transplant and maintenance therapy in plasma cell disorders.Hematology. American Society of Hematology. Education Program · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite remarkable progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) relapse and the curability of MM remains limited. Genetically defined high-risk MM represents a subgroup with an aggressive disease course despite novel agents. Allogeneic hematopoietic cell transplantation (allo-SCT) is a potentially curative option in MM that has several advantages including a tumor-free graft, and the potential for sustained immune-mediated disease control. However, historically high treatment-related mortality (TRM) and conflicting reports from prospective studies in the United States and European Union have limited the utilization of this modality. Meanwhile, newer preparative regimens, planned maintenance strategies and improvements in supportive care have led to a decline in TRM and better survival in recent years. The allo-SCT platform also provides additional options of immunotherapy at relapse including donor lymphocyte infusions, immunomodulatory drug maintenance and withdrawal of immune suppression. In this article, we provide an in-depth review of literature for allo-SCT and other immunotherapy options, as well as the authors' approach to using allo-SCT in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.